Treatment of small cell lung cancer

Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt

Standard

Treatment of small cell lung cancer. / Langer, Seppo W.; Sørensen, Morten.

Lung Cancer Therapy Annual. CRC Press, 2008. s. 91-114.

Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt

Harvard

Langer, SW & Sørensen, M 2008, Treatment of small cell lung cancer. i Lung Cancer Therapy Annual. CRC Press, s. 91-114.

APA

Langer, S. W., & Sørensen, M. (2008). Treatment of small cell lung cancer. I Lung Cancer Therapy Annual (s. 91-114). CRC Press.

Vancouver

Langer SW, Sørensen M. Treatment of small cell lung cancer. I Lung Cancer Therapy Annual. CRC Press. 2008. s. 91-114

Author

Langer, Seppo W. ; Sørensen, Morten. / Treatment of small cell lung cancer. Lung Cancer Therapy Annual. CRC Press, 2008. s. 91-114

Bibtex

@inbook{ba5a384dcbad493ba10c39fd4e105201,
title = "Treatment of small cell lung cancer",
abstract = "During the past three decades, treatment progress in small cell lung cancer (SCLC) has been modest and mainly achieved in patients staged as having limited disease (LD-SCLC) by the addition and refining of locoregional radiation to systemic chemotherapy. Three landmarks have been accomplished: (1) the addition of thoracic radiation therapy to systemic chemotherapy; (2) the demonstration of the superiority of early and/or twice-daily radiation therapy compared with late, once-daily fractionation; and (3) prophylactic radiation therapy of the brain, the so-called prophylactic cranial irradiation (PCI). Each of these innovations has contributed to an improvement of the 5-year survival rate in LD-SCLC. In contrast, progress in the treatment of patients with extensive disease (ED-SCLC) has been very modest. However, recently a significant step towards further improvement of palliative treatment has emerged with the demonstration that PCI also plays a definite role in the treatment of extensive disease.1",
author = "Langer, {Seppo W.} and Morten S{\o}rensen",
year = "2008",
month = jan,
day = "1",
language = "English",
isbn = "9780415465458",
pages = "91--114",
booktitle = "Lung Cancer Therapy Annual",
publisher = "CRC Press",

}

RIS

TY - CHAP

T1 - Treatment of small cell lung cancer

AU - Langer, Seppo W.

AU - Sørensen, Morten

PY - 2008/1/1

Y1 - 2008/1/1

N2 - During the past three decades, treatment progress in small cell lung cancer (SCLC) has been modest and mainly achieved in patients staged as having limited disease (LD-SCLC) by the addition and refining of locoregional radiation to systemic chemotherapy. Three landmarks have been accomplished: (1) the addition of thoracic radiation therapy to systemic chemotherapy; (2) the demonstration of the superiority of early and/or twice-daily radiation therapy compared with late, once-daily fractionation; and (3) prophylactic radiation therapy of the brain, the so-called prophylactic cranial irradiation (PCI). Each of these innovations has contributed to an improvement of the 5-year survival rate in LD-SCLC. In contrast, progress in the treatment of patients with extensive disease (ED-SCLC) has been very modest. However, recently a significant step towards further improvement of palliative treatment has emerged with the demonstration that PCI also plays a definite role in the treatment of extensive disease.1

AB - During the past three decades, treatment progress in small cell lung cancer (SCLC) has been modest and mainly achieved in patients staged as having limited disease (LD-SCLC) by the addition and refining of locoregional radiation to systemic chemotherapy. Three landmarks have been accomplished: (1) the addition of thoracic radiation therapy to systemic chemotherapy; (2) the demonstration of the superiority of early and/or twice-daily radiation therapy compared with late, once-daily fractionation; and (3) prophylactic radiation therapy of the brain, the so-called prophylactic cranial irradiation (PCI). Each of these innovations has contributed to an improvement of the 5-year survival rate in LD-SCLC. In contrast, progress in the treatment of patients with extensive disease (ED-SCLC) has been very modest. However, recently a significant step towards further improvement of palliative treatment has emerged with the demonstration that PCI also plays a definite role in the treatment of extensive disease.1

UR - http://www.scopus.com/inward/record.url?scp=85057669257&partnerID=8YFLogxK

M3 - Book chapter

AN - SCOPUS:85057669257

SN - 9780415465458

SP - 91

EP - 114

BT - Lung Cancer Therapy Annual

PB - CRC Press

ER -

ID: 248230845